This site is intended only for Australian Healthcare Professionals

Search

Menu

Close

Sign In or RegisterLog Out Our medicinesTherapy areasExplore contentExplore contentEventsVideosMaterialsLet’s connectLet's ConnectContact usAsk a questionPfizer Medical InformationStay connectedSuggest a topicPharmacy HubKnowledge Hub

Menu

Close

About JAKi Experience  JAKi Market Experience XELJANZ Mechanism of Action Efficacy and Safety Clinical Efficacy RA Rapid Data (ACR20) Head-to-Head Noninferiority Data (ACR50) Clinical Efficacy PsA ACR20 Data PASI75 Data Enthesitis and Dactylitis Data Clinical Efficacy UC 8-Week Efficacy Onset of Action Data 52-Week Efficacy OCTAVE Study Design Safety and Tolerability Safety in RA Safety in PsA Safety in UC Safety in ASSafety in JIAClinical Efficacy AS ASAS20/40 Data
Back Pain and Spinal Mobility Data
ASDAS(CRP) Data
Clinical Efficacy JIA
Disease Flare Data
ACR30/50/70 Data
 Dosing and Administration Dosing in RA Dosing Practical Considerations Dosing in PsA Dosing Practical Considerations Dosing in UC Dosing Practical Considerations Dosing in AS
Dosing Practical Considerations Dosing in JIA
Dosing Practical Considerations Resources and Support Resources and Support EventsMaterials Videos
Rapid reduction of signs and symptoms in RA patients*1,2*Significant reduction in the signs and symptoms of RA, as measured by ACR20, as early as week 2 and at month 31,2ORAL Solo (Study RA-I) in DMARD-IR patients2 P<0.001 vs placebo
All other time points measured were secondary endpoints.
Adapted from Fleischmann et al, 2012. ORAL Solo Study Design

A 6-month, randomized, double-blind, placebo-controlled, multicenter study in which 610 patients with moderately to severely active RA who had an inadequate response to ≥1 DMARD received XELJANZ® 5 mg BID or 10 mg BID or placebo. At month 3, all patients randomized to placebo were switched to either XELJANZ 5 mg BID or 10 mg BID. The coprimary endpoints were ACR20 response, HAQ-DI, and DAS28-4(ESR).2

Explore more Have you seen how XELJANZ performed in a head-to-head noninferiority study? Learn more ACR=American College of Rheumatology; DAS28-4(ESR)=Disease Activity Score for 28-joint counts based on erythrocyte sedimentation rate; DMARD=disease-modifying antirheumatic drug; HAQ-DI=Health Assessment Questionnaire-Disability Index; IR=inadequate responder; JAKi=Janus kinase inhibitor; PsA=psoriatic arthritis; RA=rheumatoid arthritis; UC=ulcerative colitis.Clinical Efficacy RA
SAFETY

Learn more about the XELJANZ safety profile

 See safety in RA
DOSING

Learn about dosing with XELJANZ, the first oral JAKi approved for RA

 See recommended dosing
EXPERIENCE

Find out more about the JAKi with the longest market experience in RA, PsA, UC, AS and JIA

 See XELJANZ Experience
References:Data on file. Pfizer Inc., New York, NY. 
Fleischmann R, Kremer J, Cush J, et al; for the ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495-507.

▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

WARNINGS 
XELJANZ should only be used if no suitable treatment alternatives are available in patients: 
  • with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past, long-time smokers) 
  • with malignancy risk factors (e.g. current malignancy or history of malignancy) 
  • who are 65 years of age and older. 

See PI for details, Section 4.4 Special Warnings and Precautions for Use: Mortality; Major Adverse Cardiovascular Events (including Myocardial Infarction); Thrombosis; Malignancy and Lymphoproliferative Disorder (excluding Nonmelanoma Skin Cancer [NMSC]); Skin Cancer and Use in the Elderly. 


Before prescribing, please review full Product Information available here.
 

PBS Information:  Authority required. Refer to PBS Schedule for full authority information.

®Registered Trademark.
PP-XEL-AUS-1405 08/23.
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about Pfizer medicines and vaccines.

Sign inRegisterAccountSign Out

The site is intended for Australian healthcare professionals.

 

©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.

 

PP-UNP-AUS-0551 12/23.

You are now leaving Pfizer
You are leaving PfizerPro.
You may be directed to a third-party website.
Please note third-party websites are not controlled by Pfizer or subject to our privacy policy.
 
PP-UNP-AUS-0551 12/23.